The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients
Open accessAbstract
Objectives We investigated whether atorvastatin might decrease insulin sensitivity and increase ambient glycemia in hypercholesterolemic patients.Background Clinical trials suggest that some statin treatments might increase the incidence of diabetes despite reductions in low-density lipoprotein (LDL) cholesterol and improvement in endothelial dysfunction.Methods A randomized, single-blind, placebo-controlled parallel study was conducted in 44 patients taking placebo and in 42, 44, 43, and 40 patients given daily atorvastatin 10, 20, 40, and 80 mg, respectively, during a 2-month treatment period.Results Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol (39%, 47%, 52%, and 56%, respectively) and apolipoprotein B levels (33%, 37%, 42%, and 46%, respectively) after 2 months of therapy when compared with either baseline (all p < 0.001 by paired t test) or placebo (p < 0.001 by analysis of variance [ANOVA]). Atorvastatin 10, 20, 40, and 80 mg significantly increased fasting plasma insulin (mean changes: 25%, 42%, 31%, and 45%, respectively) and glycated hemoglobin levels (2%, 5%, 5%, and 5%, respectively) when compared with either baseline (all p < 0.05 by paired t test) or placebo (p = 0.009 for insulin and p = 0.008 for glycated hemoglobin by ANOVA). Atorvastatin 10, 20, 40, and 80 mg decreased insulin sensitivity (1%, 3%, 3%, and 4%, respectively) when compared with either baseline (p = 0.312, p = 0.008, p < 0.001, and p = 0.008, respectively, by paired t test) or placebo (p = 0.033 by ANOVA).Conclusions Despite beneficial reductions in LDL cholesterol and apolipoprotein B, atorvastatin treatment resulted in significant increases in fasting insulin and glycated hemoglobin levels consistent with insulin resistance and increased ambient glycemia in hypercholesterolemic patients. (Effects of Atorvastatin on Adiponectin Levels and Insulin Sensitivity In Hypercholesterolemic Patients; NCT00745836).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The 3 studies by Koh et al. (19,20,22) from 2008, 2009, and 2010 used the Quantitative Insulin-Sensitivity Check Index as a surrogate measure for insulin sensitivity, whereas the study by Ohrvall et al. (21) from 1995 used the hyperinsulinemic-euglycemic clamp technique.”
From Simvastatin Effects on Skeletal Muscle (2013) · cites this paper as [22]
In the citing paper
“Recently, it has been reported that statin treatment impairs insulin sensitivity and increases the prevalence of type 2 diabetes (19 -22); and it seems that lipophilic statins (i.e., simvastatin, atorvastatin, fluvastatin, lovastatin) have a more pronounced effect on insulin sensitivity compared with hydrophilic statins (i.e., pravastatin, rosuvastatin) (23).”
From Simvastatin Effects on Skeletal Muscle (2013) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Self-citationSever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Kim, J.-A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006) · Circulation · doi:10.1161/circulationaha.105.563213 · Cited by 1,652
Self-citationMuniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00645.2007 · Cited by 1,643
Self-citationCardiovascular Actions of Insulin
Muniyappa, R., Montagnani, M., Koh, K. K., & Quon, M. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0006 · Cited by 888
Self-citation
Cited by
Sorted by citations
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61183-1 · Cited by 680
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab757 · Cited by 281
2018 Guidelines for the management of dyslipidemia
Rhee, E., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, B. J., Choi, S., et al. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.188 · Cited by 221
Self-citationChruściel, P., Sahebkar, A., Rembek, M., Șerban, M.-C., Ursoniu, S., Mikhailidis, D. P., Jones, S. R., Moșteoru, S., Blaha, M. J., Martin, S. S., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.897 · Cited by 195
2018 Guidelines for the Management of Dyslipidemia in Korea
Rhee, E., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, B. J., Choi, S., et al. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.78 · Cited by 194
Self-citationColhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw292 · Cited by 172
Gutierrez, M. J., Rosenberg, N. L., MacDougall, D. E., Hanselman, J. C., Margulies, J. R., Strange, P., Milad, M. A., McBride, S. J., & Newton, R. S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302677 · Cited by 170
Simvastatin Effects on Skeletal Muscle
Larsen, S., Stride, N., Hey-Mogensen, M., Hansen, C. N., Bang, L. E., Bundgaard, H., Nielsen, L. B., Helge, J. W., & Dela, F. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.036 · Cited by 165
Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00040-8 · Cited by 161
Lipid lowering efficacy of atorvastatin
Adams, S. P., Tsang, M., & Wright, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008226.pub2 · Cited by 145
Mansi, I. A., Chansard, M., Lingvay, I., Zhang, S., Halm, E. A., & Alvarez, C. A. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5714 · Cited by 144
Modulation of adiponectin as a potential therapeutic strategy
Lim, S. K., Quon, M. J., & Koh, K. K. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.051 · Cited by 140
Self-citationDifferential metabolic effects of distinct statins
Koh, K. K., Sakuma, I., & Quon, M. J. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.036 · Cited by 130
Self-citationImpact of Metabolic Syndrome on Progression of Aortic Stenosis
Capoulade, R., Clavel, M.-A., Dumesnil, J. G., Chan, K. L., Teo, K. K., Tam, J. W., Côté, N., Mathieu, P., Després, J.-P., & Pibarot, P. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.052 · Cited by 127
Nielsen, S. F., & Nordestgaard, B. G. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70173-1 · Cited by 125
Statins and the risk of new-onset diabetes
Preiss, D., & Sattar, N. A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834b4994 · Cited by 113
KONES, R. J. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s10812 · Cited by 112
Atorvastatin for lowering lipids
Adams, S. P., Tsang, M., & Wright, J. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008226.pub3 · Cited by 109
Antonopoulos, A. S., Margaritis, M., Coutinho, P., Digby, J. E., Patel, R., Psarros, C., Ntusi, N., Karamitsos, T. D., Lee, R., Silva, R. D., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303828 · Cited by 106
Statins are associated with increased insulin resistance and secretion
Abbasi, F., Lamendola, C., Harris, C. S., Harris, V., Tsai, M.-S., Tripathi, P., Abbas, F., Reaven, G. M., Reaven, P. D., Snyder, M. P., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316159 · Cited by 98
Self-citationSattar, N. A., Ginsberg, H. N., Ray, K. K., Chapman, M. J., Arca, M., Averna, M. R., Betteridge, D. J., Bhatnagar, D., Bilianou, E., Carmena, R., et al. (2014) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2014.04.001 · Cited by 99
Gumprecht, J., Gosho, M., Budinski, D., & Hounslow, N. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01477.x · Cited by 81
Macis, D., Gandini, S., Guerrieri‐Gonzaga, A., Johansson, H. A., Magni, P., Ruscica, M., Lazzeroni, M., Serrano, D., Cazzaniga, M., Mora, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2237 · Cited by 77
Hang, Y.-X., Qin, X., Ren, T., & Cao, J. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0797-2 · Cited by 76
Danaei, G., Rodríguez, L. A. G., Cantero, O. F., & Hernán, M. Á. (2012) · Diabetes Care · doi:10.2337/dc12-1756 · Cited by 72
Thongtang, N., Ai, M., Otokozawa, S., Himbergen, T. V., Asztalos, B. F., Nakajima, K., Stein, E. A., Jones, P. H., & Schaefer, E. J. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.09.031 · Cited by 68
Dugani, S. B., Akinkuolie, A. O., Paynter, N. P., Glynn, R. J., Ridker, P. M., & Mora, S. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0096 · Cited by 68
Sokooti, S., Flores-Guerrero, J. L., Heerspink, H. J. L., Connelly, M. A., Bakker, S. J. L., & Dullaart, R. P. F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01348-w · Cited by 69
Blom, D. J., Koren, M. J., Roth, E. M., Monsalvo, M. L., Djedjos, C. S., Nelson, P., Elliott, M., Wasserman, S. M., Ballantyne, C. M., & Holman, R. R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12788 · Cited by 64
Alvarez-Jimenez, L., Morales-Palomo, F., Moreno-Cabañas, A., Ortega, J. F., & Mora-Rodríguez, R. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175672 · Cited by 60
Different effects of statins on induction of diabetes mellitus: an experimental study
Zhao, S., & Wang, Z. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s87979 · Cited by 60
Bamberger, C., Rossmeier, A., Lechner, K., Li-ya, W., Waldmann, E., Stark, R. G., Altenhofer, J., Henze, K., & Parhofer, K. G. (2017) · Nutrients · doi:10.3390/nu9101097 · Cited by 60
Robinson, J. G. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000172 · Cited by 58
Role of Statins in Coronary Artery Disease
Lim, S. Y. (2013) · Chonnam Medical Journal · doi:10.4068/cmj.2013.49.1.1 · Cited by 60
Tabrizi, R., Tamtaji, O. R., Mirhosseini, N. Z., Lankarani, K. B., Akbari, M., Dadgostar, E., Borhani‐Haghighi, A., Peymani, P., Ahmadizar, F., & Asemi, Z. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.010 · Cited by 58
Statin Treatment, New-Onset Diabetes, and Other Adverse Effects: A Systematic Review
Bang, C. N., & Okin, P. M. (2014) · Current Cardiology Reports · doi:10.1007/s11886-013-0461-4 · Cited by 56
Evans, M., Rumberger, J. A., Azumano, I., Napolitano, J. J., Citrolo, D., & Kamiya, T. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s57116 · Cited by 56
New Trends in Dyslipidemia Treatment
Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 62
Self-citationStatin diabetogenicity: guidance for clinicians
Ray, K. K. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-s1-s3 · Cited by 55
Oh, P. C., Koh, K. K., Sakuma, I., Lim, S., Lee, Y., Lee, S., Lee, K., Han, S. H., & Shin, E. K. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.07.075 · Cited by 54
Self-citationKoh, K. K., Quon, M. J., Shin, K.-C., Lim, S., Lee, Y., Sakuma, I., Lee, K., Han, S. H., & Shin, E. K. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.11.018 · Cited by 61
Self-citationde Lorgeril, M., Salen, P., Defaye, P., & Rabaeus, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-5 · Cited by 53
Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients
Koh, K. K., Quon, M. J., Sakuma, I., Han, S. H., Choi, H., Lee, K., & Shin, E. K. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.028 · Cited by 53
Self-citationStatin initiation and risk of incident kidney disease in patients with diabetes
Zhou, S., Su, L., Xu, R., Li, Y., Chen, R., Cao, Y., Gao, P., Zhang, X., Luo, F., Gao, Q., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230093 · Cited by 52
Zafrir, B., & Jain, M. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6534-9 · Cited by 52
Atorvastatin: safety and tolerability
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.495385 · Cited by 53
Arnaboldi, L., & Corsini, A. (2015) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(14)70002-9 · Cited by 51
New onset diabetes mellitus induced by statins: current evidence
Chrysant, S. G. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1292107 · Cited by 49
Arsenault, B. J., Barter, P. J., DeMicco, D. A., Bao, W., Preston, G. M., LaRosa, J. C., Grundy, S. M., DEEDWANIA, P. C., Greten, H., WENGER, N. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114519 · Cited by 48
Drug‐Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism
Anyanwagu, U., IDRIS, I. R., & Donnelly, R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.274 · Cited by 49
A Review of Exercise as Medicine in Cardiovascular Disease: Pathology and Mechanism
Gronek, P., Wieliński, D., Cygański, P., Rynkiewicz, A., Zając, A., Maszczyk, A., Gronek, J., Podstawski, R., Czarny, W., Balkó, Š., et al. (2020) · Aging and Disease · doi:10.14336/ad.2019.0516 · Cited by 53
Livingstone, S. J., Looker, H. C., Akbar, T., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Fuller, J., & Colhoun, H. M. (2015) · Diabetologia · doi:10.1007/s00125-015-3802-6 · Cited by 46
Mechanisms of insulin resistance by simvastatin in C2C12 myotubes and in mouse skeletal muscle
Sanvee, G. M., Panajatovic, M. V., Bouitbir, J., & Krähenbühl, S. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.02.025 · Cited by 46
Anagnostis, P. G., Selalmatzidou, D., Pοlyzos, S. A., Panagiotou, A., Slavakis, A., Panagiotidou, A., Athyros, V. G., Karagiannis, A. I., Mikhailidis, D. P., & Kita, M. D. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02655.x · Cited by 44
Goldstein, M. R., & Mascitelli, L. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0368-x · Cited by 40
Nakagomi, A., Shibui, T., Kohashi, K., Kosugi, M., Kusama, Y., Atarashi, H., & Shimizu, W. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.29520 · Cited by 41
Lee, H., Sakuma, I., Ihm, S., Goh, C.-W., & Koh, K. K. (2014) · Circulation Journal · doi:10.1253/circj.cj-13-1494 · Cited by 40
Self-citationUydu, H. A., Yıldırmış, S., Örem, C., Calapoğlu, M., Alver, A., Kural, B. V., & Örem, A. (2012) · The Journal of Membrane Biology · doi:10.1007/s00232-012-9441-7 · Cited by 38
Statins and the brain: New perspective for old drugs
Ling, Q., & Tejada-Simon, M. V. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.013 · Cited by 43
Kılıç, Ü., Gök, Ö., Elibol, B., Uysal, Ö., & Bacaksız, A. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12362 · Cited by 38
Statin Use and the Risk of Incident Diabetes Mellitus: A Review of the Literature
Colbert, J. D., & Stone, J. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.021 · Cited by 37
Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
Nakajima, K. (2012) · International Journal of Hepatology · doi:10.1155/2012/950693 · Cited by 37
Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases
Nguyễn, T. T. B., Jin, Y., & Chung, H. (2017) · Molecules · doi:10.3390/molecules22101795 · Cited by 39
Shi, M., Yang, A., Lau, E. S. H., Luk, A. O. Y., Ronald, C. W., Kong, A. P. S., Wong, R. S. M., Chan, J. C. M., Chan, J. C. N., & Chow, E. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004369 · Cited by 37
Lim, S. K., Sakuma, I., Quon, M. J., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.037 · Cited by 36
Self-citationAngelidi, A. M., Stambolliu, E., Adamopoulou, K., & Kousoulis, A. A. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8380192 · Cited by 37
Koh, K. K., Oh, P. C., Sakuma, I., Kim, E. Y., Lee, Y., Hayashi, T., Han, S. H., Park, Y. M., & Shin, E. K. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.016 · Cited by 34
Self-citationLoughrey, B. V., McGinty, A., Young, I. S., McCance, D. R., & Powell, L. A. (2012) · Clinical Endocrinology · doi:10.1111/cen.12113 · Cited by 34
Cardiovascular drugs that increase the risk of new-onset diabetes
Ong, K. L., Barter, P. J., & Waters, D. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2013.12.025 · Cited by 33
Statins and diabetes risk: Fact, fiction, and clinical implications
Rocco, M. B. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12091 · Cited by 32
Efficacy and safety of Zhibitai in treating coronary heart disease patients with hyperlipemia
Chen, M., Li, Y., Men, L., Zhang, Z., Zhong, X., Yang, S., & Luan, J. (2020) · Medicine · doi:10.1097/md.0000000000021991 · Cited by 32
Is statin‐induced diabetes clinically relevant? A comprehensive review of the literature
Bell, D. S. H., DiNicolantonio, J. J., & O’Keefe, J. H. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12254 · Cited by 32
Navarese, E. P., Szczesniak, A. M., Kołodziejczak, M. M., Górny, B., Kubica, J., & Suryapranata, H. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0053-0 · Cited by 32
How to balance cardiorenometabolic benefits and risks of statins
Lim, S. K., Oh, P. C., Sakuma, I., & Koh, K. K. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.001 · Cited by 31
Self-citationSimvastatin Inhibits Glucose Metabolism and Legumain Activity in Human Myotubes
Smith, R. L., Solberg, R., Jacobsen, L. L., Voreland, A. L., Rustan, A. C., Thoresen, G. H., & Johansen, H. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085721 · Cited by 29
The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review
Abohelwa, M., Kopel, J. J., Shurmur, S. W., Ansari, M. M., Awasthi, S., & Awasthi, S. (2023) · Journal of Vascular Diseases · doi:10.3390/jvd2010010 · Cited by 43
Koh, K. K., Lim, S. K., Choi, H., Lee, Y., Han, S. H., Lee, K., Oh, P. C., Sakuma, I., Shin, E. K., & Quon, M. J. (2013) · Diabetes · doi:10.2337/db13-0566 · Cited by 28
Self-citationKokkinos, P. F., Faselis, C. J., Narayan, P., MYERS, J. N., Nylén, E., Sui, X., Zhang, J., & Lavie, C. J. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.042 · Cited by 29
Statin-Associated Incident Diabetes: A Literature Review
Park, Z. H., Juska, A., Dyakov, D., & Patel, R. V. (2014) · The Consultant Pharmacist · doi:10.4140/tcp.n.2014.317 · Cited by 27
Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?
Nsaibia, M. J., Devendran, A. S., Goubaa, E., Bouitbir, J., Capoulade, R., & Bouchareb, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123331 · Cited by 24
Differential Metabolic Actions of Specific Statins: Clinical and Therapeutic Considerations
Lim, S. K., Sakuma, I., Quon, M. J., & Koh, K. K. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5531 · Cited by 25
Self-citationCaliman, I. F., Lamas, A. Z., Dalpiaz, P. L. M., Medeiros, A. R. S., Abreu, G. R., de Figueiredo, S. G., Gusmão, L. N., de Andrade, T. U., & Bissoli, N. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080892 · Cited by 25
Use of Statins and the Risk of Incident Diabetes: A Retrospective Cohort Study
Olotu, B., Shepherd, M. D., Novak, S., Lawson, K. A., Wilson, J. P., Richards, K. M., & Rasu, R. S. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0176-1 · Cited by 25
Cai, R., Yuan, Y., Sun, J., Xia, W., Huang, R., Tian, S., Dong, X., Shen, Y., & Wang, S. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1220539 · Cited by 27
Statins Aggravate the Risk of Insulin Resistance in Human Muscle
Grunwald, S. A., Haafke, S., Grieben, U. I., Kassner, U., Steinhagen‐Thiessen, E., & Spuler, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042398 · Cited by 24
Caveats to aggressive lowering of lipids by specific statins
Koh, K. K., Lim, S. K., Sakuma, I., & Quon, M. J. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.09.002 · Cited by 24
Self-citationCurrie, O., Mangin, D. A., Williman, J. A., McKinnon-Gee, B., & Bridgford, P. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003475 · Cited by 24
Koh, K. K., Sakuma, I., Shimada, K., Hayashi, T., & Quon, M. J. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.0406 · Cited by 24
Self-citationSaito, I., Azuma, K., Kakikawa, T., Oshima, N., Hanson, M. E., & Tershakovec, A. M. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0036-z · Cited by 23
Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits
Cho, K. I., Sakuma, I., Sohn, I. S., Hayashi, T., Shimada, K., & Koh, K. K. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1445 · Cited by 23
Self-citationKoh, K. K., Oh, P. C., Sakuma, I., Lee, Y., Han, S. H., & Shin, E. K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.051 · Cited by 22
Self-citationZhao, Y., Peng, R., Zhao, W., Liu, Q., Guo, Y., Zhao, S., & Xu, D. (2017) · Medicine · doi:10.1097/md.0000000000006104 · Cited by 22
Asping, M., Stride, N. O., Søgaard, D., Dohlmann, T. L., Helge, J. W., Dela, F., & Larsen, S. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2224-4 · Cited by 22
Role of bile acid sequestrants in the treatment of type 2 diabetes
Takebayashi, K. (2010) · World Journal of Diabetes · doi:10.4239/wjd.v1.i5.146 · Cited by 22
Effect of atorvastatin on testosterone levels
Shawish, M. I., Bagheri, B., Musini, V. M., Adams, S. P., & Wright, J. M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013211.pub2 · Cited by 22
Li, H., Lin, H., Zhao, H.-Y., Yang, X., Cheng, Y., Shen, P., & Zhan, S. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s158850 · Cited by 21
Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia
Koh, K. K., Quon, M. J., Sakuma, I., Lee, Y., Lim, S. K., Han, S. H., & Shin, E. K. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.10.103 · Cited by 20
Self-citationMansi, I. A., Sumithran, P., & Kinaan, M. (2023) · BMJ · doi:10.1136/bmj-2022-071727 · Cited by 20
EFFECT OF COSMOS CAUDATUS KUNTH LEAVES ON THE LIPID PROFILE OF A HYPERLIPIDEMIA-INDUCED ANIMAL MODEL
Perumal, V., Hamid, A. A., Ismail, A., Shaari, K., Abas, F., Ismail, I. S., Maulidiani, M., Lajis, N. H., & Khatib, A. (2014) · The International Islamic University Malaysia Repository (The International Islamic University Malaysia) · Cited by 19
Metadata
- Authors
- Koh, K. K., Quon, M. J., Han, S. H., Lee, Y., Kim, S. J., & Shin, E. K.
- Affiliations
- Gachon University Gil Medical Center (KR)
- National Institutes of Health (US)
- University of Seoul (KR)
- Corresponding author
- Koh, Kwang Kon
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 55
- Issue
- 12
- Pages
- 1209-1216
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC3016087
- OpenAlex
- W2052703897
- Cited by
- 229
- References
- 27
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 9 · 2023: 16 · 2022: 9 · 2021: 8 · 2020: 5 · 2019: 13 · 2018: 9 · 2017: 11 · 2016: 13 · 2015: 18 · 2014: 31 · 2013: 23 · 2012: 23
- FWCI
- 24.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- established investigator award
- Gachon University Gil Hospital
- Intramural Research Program, National Center for Complementary and Alternative Medicine, National Institutes of Health
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- atorvastatin, insulin resistance, hypercholesterolemia, statins, fasting insulin, HbA1c, LDL cholesterol, apolipoprotein B, diabetes risk, dose-dependent effects, endothelial dysfunction, endothelial nitric oxide synthase, nitric oxide, nitric oxide synthase inhibition, hypertriglyceridemia
- MeSH terms
- Atorvastatin, Adult, Aged, Blood Glucose, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Insulin, Insulin Resistance, Male, Middle Aged, Pyrroles, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
